LIVING WITH CRC
Severe immune-related side effects studied in 1,175 MSI-H digestive cancer patients on immunotherapyAn international study of 1,175 patients from 34 centers examined how grade 3 or higher immune-related adverse events correlate with progression-free survival and overall survival in patients with dMMR/MSI-H digestive cancers treated with immune checkpoint inhibitors. (Journal for ImmunoTherapy of Cancer)